Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2023 · 10-Q
Revenue$7.40K$7.40K— vs Q1 2022 Net Income-$2.76M-$2.76MN/M vs Q1 2022 EPS Diluted-$0.01-$0.01N/M vs Q1 2022 Operating Income-$710,634N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Margins · derivedOperating margin-9607.1%
Net margin-37348.0%
ended Mar 31, 2023 · filed May 22, 2023 · 52 d after period end